Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up

Carlo Gambacorti-Passerini, Tim H. Brümmendorf, Dong Wook Kim, Anna G. Turkina, T. Masszi, Sarit Assouline, Simon Durrant, Hagop M. Kantarjian, H. Jean Khoury, Andrey Zaritskey, Zhi Xiang Shen, Jie Jin, Edo Vellenga, Ricardo Pasquini, Vikram Mathews, Francisco Cervantes, Nadine Besson, Kathleen Turnbull, Eric Leip, Virginia KellyJorge E. Cortes

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Bosutinib is an orally active, dual Src/Abl tyrosine kinase inhibitor for treatment of chronic myeloid leukemia (CML) following resistance/intolerance to prior therapy. Here, we report the data from the 2-year follow-up of a phase 1/2 open-label study evaluating the efficacy and safety of bosutinib as second-line therapy in 288 patients with chronic phase CML resistant (n=200) or intolerant (n=88) to imatinib. The cumulative response rates to bosutinib were as follows: 85% achieved/maintained complete hematologic response, 59% achieved/maintained major cytogenetic response (including 48% with complete cytogenetic response), and 35% achieved major molecular response. Responses were durable, with 2-year estimates of retaining response >70%. Two-year probabilities of progression-free survival and overall survival were 81% and 91%, respectively. The most common toxicities were primarily gastrointestinal adverse events (diarrhea [84%], nausea [45%], vomiting [37%]), which were primarily mild to moderate, typically transient, and first occurred early during treatment. Thrombocytopenia was the most common grade 3/4 hematologic laboratory abnormality (24%). Outcomes were generally similar among imatinib-resistant and imatinib-intolerant patients and did not differ with age. The longer-term results of the present analysis confirm that bosutinib is an effective and tolerable second-line therapy for patients with imatinib-resistant or imatinib-intolerant chronic phase CML. ClinicalTrials.gov Identifier: NCT00261846. Am. J. Hematol. 89:732-742, 2014.

Original languageEnglish
Pages (from-to)732-742
Number of pages11
JournalAmerican Journal of Hematology
Volume89
Issue number7
DOIs
Publication statusPublished - 2014

Fingerprint

Leukemia, Myeloid, Chronic Phase
Safety
Cytogenetics
Therapeutics
src-Family Kinases
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Thrombocytopenia
Nausea
Disease-Free Survival
Vomiting
Diarrhea
Imatinib Mesylate
bosutinib
Survival

ASJC Scopus subject areas

  • Hematology

Cite this

Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance : Minimum 24-month follow-up. / Gambacorti-Passerini, Carlo; Brümmendorf, Tim H.; Kim, Dong Wook; Turkina, Anna G.; Masszi, T.; Assouline, Sarit; Durrant, Simon; Kantarjian, Hagop M.; Khoury, H. Jean; Zaritskey, Andrey; Shen, Zhi Xiang; Jin, Jie; Vellenga, Edo; Pasquini, Ricardo; Mathews, Vikram; Cervantes, Francisco; Besson, Nadine; Turnbull, Kathleen; Leip, Eric; Kelly, Virginia; Cortes, Jorge E.

In: American Journal of Hematology, Vol. 89, No. 7, 2014, p. 732-742.

Research output: Contribution to journalArticle

Gambacorti-Passerini, C, Brümmendorf, TH, Kim, DW, Turkina, AG, Masszi, T, Assouline, S, Durrant, S, Kantarjian, HM, Khoury, HJ, Zaritskey, A, Shen, ZX, Jin, J, Vellenga, E, Pasquini, R, Mathews, V, Cervantes, F, Besson, N, Turnbull, K, Leip, E, Kelly, V & Cortes, JE 2014, 'Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up', American Journal of Hematology, vol. 89, no. 7, pp. 732-742. https://doi.org/10.1002/ajh.23728
Gambacorti-Passerini, Carlo ; Brümmendorf, Tim H. ; Kim, Dong Wook ; Turkina, Anna G. ; Masszi, T. ; Assouline, Sarit ; Durrant, Simon ; Kantarjian, Hagop M. ; Khoury, H. Jean ; Zaritskey, Andrey ; Shen, Zhi Xiang ; Jin, Jie ; Vellenga, Edo ; Pasquini, Ricardo ; Mathews, Vikram ; Cervantes, Francisco ; Besson, Nadine ; Turnbull, Kathleen ; Leip, Eric ; Kelly, Virginia ; Cortes, Jorge E. / Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance : Minimum 24-month follow-up. In: American Journal of Hematology. 2014 ; Vol. 89, No. 7. pp. 732-742.
@article{bbf457a3b32948b1a1716ce0d33cd779,
title = "Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up",
abstract = "Bosutinib is an orally active, dual Src/Abl tyrosine kinase inhibitor for treatment of chronic myeloid leukemia (CML) following resistance/intolerance to prior therapy. Here, we report the data from the 2-year follow-up of a phase 1/2 open-label study evaluating the efficacy and safety of bosutinib as second-line therapy in 288 patients with chronic phase CML resistant (n=200) or intolerant (n=88) to imatinib. The cumulative response rates to bosutinib were as follows: 85{\%} achieved/maintained complete hematologic response, 59{\%} achieved/maintained major cytogenetic response (including 48{\%} with complete cytogenetic response), and 35{\%} achieved major molecular response. Responses were durable, with 2-year estimates of retaining response >70{\%}. Two-year probabilities of progression-free survival and overall survival were 81{\%} and 91{\%}, respectively. The most common toxicities were primarily gastrointestinal adverse events (diarrhea [84{\%}], nausea [45{\%}], vomiting [37{\%}]), which were primarily mild to moderate, typically transient, and first occurred early during treatment. Thrombocytopenia was the most common grade 3/4 hematologic laboratory abnormality (24{\%}). Outcomes were generally similar among imatinib-resistant and imatinib-intolerant patients and did not differ with age. The longer-term results of the present analysis confirm that bosutinib is an effective and tolerable second-line therapy for patients with imatinib-resistant or imatinib-intolerant chronic phase CML. ClinicalTrials.gov Identifier: NCT00261846. Am. J. Hematol. 89:732-742, 2014.",
author = "Carlo Gambacorti-Passerini and Br{\"u}mmendorf, {Tim H.} and Kim, {Dong Wook} and Turkina, {Anna G.} and T. Masszi and Sarit Assouline and Simon Durrant and Kantarjian, {Hagop M.} and Khoury, {H. Jean} and Andrey Zaritskey and Shen, {Zhi Xiang} and Jie Jin and Edo Vellenga and Ricardo Pasquini and Vikram Mathews and Francisco Cervantes and Nadine Besson and Kathleen Turnbull and Eric Leip and Virginia Kelly and Cortes, {Jorge E.}",
year = "2014",
doi = "10.1002/ajh.23728",
language = "English",
volume = "89",
pages = "732--742",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "7",

}

TY - JOUR

T1 - Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance

T2 - Minimum 24-month follow-up

AU - Gambacorti-Passerini, Carlo

AU - Brümmendorf, Tim H.

AU - Kim, Dong Wook

AU - Turkina, Anna G.

AU - Masszi, T.

AU - Assouline, Sarit

AU - Durrant, Simon

AU - Kantarjian, Hagop M.

AU - Khoury, H. Jean

AU - Zaritskey, Andrey

AU - Shen, Zhi Xiang

AU - Jin, Jie

AU - Vellenga, Edo

AU - Pasquini, Ricardo

AU - Mathews, Vikram

AU - Cervantes, Francisco

AU - Besson, Nadine

AU - Turnbull, Kathleen

AU - Leip, Eric

AU - Kelly, Virginia

AU - Cortes, Jorge E.

PY - 2014

Y1 - 2014

N2 - Bosutinib is an orally active, dual Src/Abl tyrosine kinase inhibitor for treatment of chronic myeloid leukemia (CML) following resistance/intolerance to prior therapy. Here, we report the data from the 2-year follow-up of a phase 1/2 open-label study evaluating the efficacy and safety of bosutinib as second-line therapy in 288 patients with chronic phase CML resistant (n=200) or intolerant (n=88) to imatinib. The cumulative response rates to bosutinib were as follows: 85% achieved/maintained complete hematologic response, 59% achieved/maintained major cytogenetic response (including 48% with complete cytogenetic response), and 35% achieved major molecular response. Responses were durable, with 2-year estimates of retaining response >70%. Two-year probabilities of progression-free survival and overall survival were 81% and 91%, respectively. The most common toxicities were primarily gastrointestinal adverse events (diarrhea [84%], nausea [45%], vomiting [37%]), which were primarily mild to moderate, typically transient, and first occurred early during treatment. Thrombocytopenia was the most common grade 3/4 hematologic laboratory abnormality (24%). Outcomes were generally similar among imatinib-resistant and imatinib-intolerant patients and did not differ with age. The longer-term results of the present analysis confirm that bosutinib is an effective and tolerable second-line therapy for patients with imatinib-resistant or imatinib-intolerant chronic phase CML. ClinicalTrials.gov Identifier: NCT00261846. Am. J. Hematol. 89:732-742, 2014.

AB - Bosutinib is an orally active, dual Src/Abl tyrosine kinase inhibitor for treatment of chronic myeloid leukemia (CML) following resistance/intolerance to prior therapy. Here, we report the data from the 2-year follow-up of a phase 1/2 open-label study evaluating the efficacy and safety of bosutinib as second-line therapy in 288 patients with chronic phase CML resistant (n=200) or intolerant (n=88) to imatinib. The cumulative response rates to bosutinib were as follows: 85% achieved/maintained complete hematologic response, 59% achieved/maintained major cytogenetic response (including 48% with complete cytogenetic response), and 35% achieved major molecular response. Responses were durable, with 2-year estimates of retaining response >70%. Two-year probabilities of progression-free survival and overall survival were 81% and 91%, respectively. The most common toxicities were primarily gastrointestinal adverse events (diarrhea [84%], nausea [45%], vomiting [37%]), which were primarily mild to moderate, typically transient, and first occurred early during treatment. Thrombocytopenia was the most common grade 3/4 hematologic laboratory abnormality (24%). Outcomes were generally similar among imatinib-resistant and imatinib-intolerant patients and did not differ with age. The longer-term results of the present analysis confirm that bosutinib is an effective and tolerable second-line therapy for patients with imatinib-resistant or imatinib-intolerant chronic phase CML. ClinicalTrials.gov Identifier: NCT00261846. Am. J. Hematol. 89:732-742, 2014.

UR - http://www.scopus.com/inward/record.url?scp=84902843429&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902843429&partnerID=8YFLogxK

U2 - 10.1002/ajh.23728

DO - 10.1002/ajh.23728

M3 - Article

C2 - 24711212

AN - SCOPUS:84902843429

VL - 89

SP - 732

EP - 742

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 7

ER -